Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06CKX
|
|||
| Former ID |
DCL000386
|
|||
| Drug Name |
SB-649868
|
|||
| Synonyms |
380899-24-1; UNII-1L1V1K2M4V; SB 649868; 1L1V1K2M4V; SB649868; GTPL4461; N-[[(2S)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]piperidin-2-yl]methyl]-1-benzofuran-4-carboxamide; SCHEMBL8045969; CHEMBL1272307; DTXSID90191491; EX-A2570; BDBM50417257; AKOS027323765; CS-7584; SB19110; HY-10806; SB-649,868; N-((1-((5-(4-Fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide; 4-Benzofurancarboxamide, N-(((2S)-1-((5-(4-fluorophenyl)-2-m
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Insomnia [ICD-11: 7A00-7A0Z] | Phase 2 | [1], [2] | |
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H24FN3O3S
|
|||
| Canonical SMILES |
CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCCC3CNC(=O)C4=C5C=COC5=CC=C4
|
|||
| InChI |
1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1
|
|||
| InChIKey |
ZJXIUGNEAIHSBI-IBGZPJMESA-N
|
|||
| CAS Number |
CAS 380899-24-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| SuperDrug ATC ID |
D05AX01
|
|||
| SuperDrug CAS ID |
cas=000110178
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Orexin receptor type 1 (HCRTR1) | Target Info | Antagonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4461). | |||
| REF 2 | ClinicalTrials.gov (NCT00426816) To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.